Harpoon Therapeutics Beheer

Beheer criteriumcontroles 3/4

De CEO Harpoon Therapeutics is Julie Eastland, benoemd in Nov2021, heeft een ambtstermijn van 2.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.16M, bestaande uit 48.7% salaris en 51.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.016% van de aandelen van het bedrijf, ter waarde $ 80.60K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.4 jaar en 5.5 jaar.

Belangrijke informatie

Julie Eastland

Algemeen directeur

US$1.2m

Totale compensatie

Percentage CEO-salaris	48.7%
Dienstverband CEO	2.3yrs
Eigendom CEO	0.02%
Management gemiddelde ambtstermijn	1.4yrs
Gemiddelde ambtstermijn bestuur	5.5yrs

Recente managementupdates

Recent updates

Improved Revenues Required Before Harpoon Therapeutics, Inc. (NASDAQ:HARP) Stock's 97% Jump Looks Justified

Jan 30

Harpoon Therapeutics, Inc. (NASDAQ:HARP) Looks Inexpensive After Falling 55% But Perhaps Not Attractive Enough

Oct 01

Analysts Just Made A Notable Upgrade To Their Harpoon Therapeutics, Inc. (NASDAQ:HARP) Forecasts

Aug 14

Forecast: Analysts Think Harpoon Therapeutics, Inc.'s (NASDAQ:HARP) Business Prospects Have Improved Drastically

May 28

Here's Why We're A Bit Worried About Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Situation

Jul 30

Harpoon Therapeutics: A T-Cell Engager Platform And A Negative Enterprise Value Makes It A Candidate For My 'Bio Boom' Portfolio

Jul 07

Is Harpoon Therapeutics (NASDAQ:HARP) In A Good Position To Invest In Growth?

Mar 08

We're Keeping An Eye On Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Rate

Nov 30

Harpoon Therapeutics: A First Look

Sep 16

Harpoon shares slide after early-stage prostate cancer study data fails to impress

Jun 04

Analyse CEO-vergoeding

Hoe is Julie Eastland's beloning veranderd ten opzichte van Harpoon Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2023	n/a	n/a	-US$30m
Jun 30 2023	n/a	n/a	-US$40m
Mar 31 2023	n/a	n/a	-US$59m
Dec 31 2022	US$1m	US$565k	-US$68m
Sep 30 2022	n/a	n/a	-US$71m
Jun 30 2022	n/a	n/a	-US$76m
Mar 31 2022	n/a	n/a	-US$75m
Dec 31 2021	US$2m	US$84k	-US$117m

Compensatie versus markt: De totale vergoeding ($USD 1.16M ) Julie } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.24M ).

Compensatie versus inkomsten: De vergoeding van Julie is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Julie Eastland (59 yo)

2.3yrs

Tenure

US$1,160,774

Compensatie

Ms. Julie M. Eastland, M.B.A. served as Chief Operating Officer and Chief Financial Officer at Recode Therapeutics, Inc. since October 2020 until November 2021. She serves as the President and Chief Execut...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Julie Eastland	President	2.3yrs	US$1.16m	0.016% $ 80.6k
Luke Walker	Chief Medical Officer	1.4yrs	US$668.96k	0% $ 0
Michael Faerm	Interim Chief Financial Officer	no data	geen gegevens	geen gegevens
Chatan Charan	Senior Vice President of Product Development	1.3yrs	geen gegevens	geen gegevens
James Bucher	Chief Legal Officer	less than a year	geen gegevens	geen gegevens
Wendy Chang	Chief People Officer	1.7yrs	geen gegevens	geen gegevens
Banmeet Anand	Senior Vice President of Translational Medicine	1.7yrs	geen gegevens	geen gegevens
Haibo Wang	Senior Vice President of Business Development	less than a year	geen gegevens	geen gegevens

1.4yrs

Gemiddelde duur

56.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van HARP wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.4 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Julie Eastland	President	5.4yrs	US$1.16m	0.016% $ 80.6k
Ronald Hunt	Independent Director	6.8yrs	US$59.56k	0.036% $ 179.5k
Joseph Bailes	Independent Director	4yrs	US$58.56k	0% $ 0
Lauren Silvernail	Independent Director	1.5yrs	US$37.76k	0% $ 0
Eric Small	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Jeffrey Ravetch	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Jonathan Drachman	Independent Director	5.5yrs	US$58.56k	0% $ 0
Charles Rudin	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Scott Myers	Independent Chairman of the Board	5.6yrs	US$109.62k	0.083% $ 406.5k
Andrew Robbins	Independent Director	4yrs	US$62.06k	0% $ 0
Mark Chin	Independent Director	6.8yrs	US$59.56k	0.036% $ 179.5k
Ramy Ibrahim	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens

5.5yrs

Gemiddelde duur

58.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van HARP wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.5 jaar).

Harpoon Therapeutics Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Harpoon Therapeutics, Inc. Announces Board Changes

Harpoon Therapeutics, Inc. Appoints Haibo Wang as Senior Vice President of Business Development

Insufficient new directors

Insufficient new directors

Harpoon Therapeutics, Inc. Appoints Luke Walker, M.D., as Chief Medical Officer

Harpoon Therapeutics Appoints Lauren Silvernail to Board of Directors

Recent updates

Harpoon Therapeutics Files Form 15

Harpoon Therapeutics, Inc.(NasdaqCM:HARP) dropped from NASDAQ Composite Index

Improved Revenues Required Before Harpoon Therapeutics, Inc. (NASDAQ:HARP) Stock's 97% Jump Looks Justified

Consensus estimates of losses per share improve by 16%

Merck Sharp & Dohme LLC entered into an agreement to acquire Harpoon Therapeutics, Inc. (NasdaqCM:HARP) for $410 million.

Merck Sharp & Dohme LLC entered into an agreement to acquire Harpoon Therapeutics, Inc. (NasdaqCM:HARP) for $410 million.

Merck Sharp & Dohme LLC entered into an agreement to acquire Harpoon Therapeutics, Inc. (NasdaqCM:HARP) for $410 million.

Price target increased by 16% to US$16.33

Harpoon Therapeutics, Inc. Announces Board Changes

Harpoon Therapeutics, Inc. Presents HPN217 Phase 1 Clinical Data in Relapsed/Refractory Multiple Myeloma (RRMM) at ASH2023 and Announces Selection of Recommended Phase 2 Dose (RP2D)

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Shareholder dilution

Consensus EPS estimates upgraded to US$4.44 loss

Harpoon Therapeutics, Inc. announced that it expects to receive $100.162904 million in funding from a group of investors

New major risk - Share price stability

Harpoon Therapeutics, Inc. (NASDAQ:HARP) Looks Inexpensive After Falling 55% But Perhaps Not Attractive Enough

Harpoon Therapeutics Receives Non-Compliance Notice from Nasdaq

Harpoon Therapeutics, Inc. Announces Presentation of Interim Data for 2.15 to 12 mg Target Dose Cohorts from its Phase 1 Clinical Trial Evaluating Single-Agent HPN217 in Relapsed/Refractory Multiple Myeloma

Consensus EPS estimates fall by 52%

Price target decreased by 14% to US$45.83

Consensus estimates of losses per share improve by 10%

Forecast to breakeven in 2024

Consensus revenue estimates increase by 57%

Analysts Just Made A Notable Upgrade To Their Harpoon Therapeutics, Inc. (NASDAQ:HARP) Forecasts

Price target increased by 11% to US$5.33

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Harpoon Therapeutics, Inc. Appoints Haibo Wang as Senior Vice President of Business Development

Insufficient new directors

Price target decreased by 9.8% to US$4.81

Harpoon Therapeutics, Inc. Announces Completion of Planned Patient Enrollment in Phase 1 Study of Hpn217 in Relapsed/Refractory Multiple Myeloma

Forecast: Analysts Think Harpoon Therapeutics, Inc.'s (NASDAQ:HARP) Business Prospects Have Improved Drastically

Consensus EPS estimates upgraded to US$1.12 loss

Forecast to breakeven in 2024

Consensus EPS estimates fall by 20%, revenue upgraded

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 20% to US$5.43

Consensus revenue estimates fall by 45%

Insufficient new directors

Full year 2022 earnings: EPS and revenues miss analyst expectations

Harpoon Therapeutics (NASDAQ:HARP) Will Have To Spend Its Cash Wisely

Harpoon Therapeutics, Inc. Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma

Harpoon Therapeutics Receives a Letter from Nasdaq Regarding Minimum Closing Bid Price

Consensus revenue estimates increase by 28%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Harpoon Therapeutics, Inc. Appoints Luke Walker, M.D., as Chief Medical Officer

Harpoon Therapeutics appoints Luke Walker as CMO

Harpoon Therapeutics Appoints Lauren Silvernail to Board of Directors

Harpoon Therapeutics: A Well Undervalued Tri-Specific Oncology Player

Price target decreased to US$8.78

Price target decreased to US$10.67

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Harpoon Therapeutics, Inc. Announces Resignation of Georgia L. Erbez as Chief Financial Officer, Effective August 31, 2022

Here's Why We're A Bit Worried About Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Situation

Harpoon Therapeutics: A T-Cell Engager Platform And A Negative Enterprise Value Makes It A Candidate For My 'Bio Boom' Portfolio

Harpoon Therapeutics, Inc. Announces Executive Appointments

Harpoon Therapeutics, Inc.(NasdaqGS:HARP) dropped from Russell 2000 Growth Index

Harpoon Therapeutics, Inc. Presents Interim Data from Ongoing Dose Escalation Portion of T Cell Engager HPN328 Clinical Trial

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Harpoon Therapeutics, Inc., Annual General Meeting, Jun 22, 2022

Price target decreased to US$14.50

Harpoon Therapeutics, Inc. Presents Preclinical Data for TriTAC-XR Platform that Supports Potential for Improved Safety by Minimizing Cytokine Release Syndrome

Natalie Sacks to Leave Harpoon Therapeutics, Inc. as Chief Medical Officer, Effective June 1, 2022

Consensus forecasts updated

Price target decreased to US$23.00

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Harpoon Therapeutics (NASDAQ:HARP) In A Good Position To Invest In Growth?

Harpoon Therapeutics Receives FDA Fast Track Designation for HPN217

Harpoon Therapeutics Receives FDA Fast Track Designation for HPN217